Drug Trial Radar · NCT07371650
This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
105
Planned (sponsor's estimate)
Start
Dec 15, 2025
Primary completion
Dec 2026
Study completion Jan 2027
Sponsor
- Lead sponsor
- Traws Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an early-stage clinical trial to determine a safe and effective dose for Tivoxavir Marboxil (TRX-100) in patients with mild to moderate Influenza. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results.
Conditions
- Influenza
Interventions
TRX-100Drug
CEN inhibitor, dosage form - capsules, dosing regimen - QD
Standard of Care (SOC)Drug
Standard of Care Influenza Antiviral therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of AE/SAETime frame: up to Day 28
- Incidence of abnormal laboratory tests resultsTime frame: Up to Day 28
- Incidence of abnormal clinically significant ECG resultsTime frame: Up to 28 days
- Number of participants with abnormal physical examinations findingsTime frame: Up to 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novatrials
Charlestown, New South Wales, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.